KY Biotechnology & Medical Research

NovaBridge Biosciences (NBP)

Track

NovaBridge Biosciences experienced seven insider trading transactions over the past ninety days, totaling 132,672.52 USD in sales. These divestments occurred following the June 2026 earnings report, amid a 19% decline in share value. Executives, including the SVP of Clinical Development and Chief Medical Officer, offloaded equity while the stock trades near its annual low.
Ticker: NBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for NovaBridge Biosciences. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Xu Cong Claire SVP, Clinical Development Officer
Transaction date
Sale
Price
103.47
Quantity 14,336 +20.3%
Value US$2,387,523
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Sale
Price
433.81
Quantity 67,688 -17.3%
Value US$2,534,985
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Sale
Price
71.77
Quantity 19,334 -27.1%
Value US$4,886,838
Xu Cong Claire SVP, Clinical Development Officer
Transaction date
Sale
Price
3.94
Quantity 3,494 -1.2%
Value US$13,766
Cao Sean Wuxiong See Remarks Executive Director
Transaction date
Sale
Price
1.99
Quantity 21,399 -37.9%
Value US$42,584
Cao Sean Wuxiong See Remarks Executive Director
Transaction date
Sale
Price
1.99
Quantity 21,399 -37.9%
Value US$42,584
Cao Sean Wuxiong Officer; CHIEF BUSINESS DEVELOPMENT OFFICER Officer
Transaction date
Proposed sale
Price
1.99
Quantity 9,304
Value US$18,534
Hagler Mark Arnold See Remarks Officer
Transaction date
Purchase
Price
2.51
Quantity 230,000 +inf%
Value US$577,300
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.79
Quantity 3,638
Value US$10,153
Skelton Joseph W. Officer; FORMER CFO Officer
Transaction date
Proposed sale
Price
4.33
Quantity 120,000
Value US$519,600
Dennis Phillip Andrew CHIEF MEDICAL OFFICER Officer
Transaction date
Proposed sale
Price
4.23
Quantity 3,431
Value US$14,501
KANNAN RAJ Officer; CEO Officer
Transaction date
Proposed sale
Price
1.39
Quantity 50,000
Value US$69,500
KANNAN RAJ Officer; CEO Officer
Transaction date
Proposed sale
Price
1.63
Quantity 300,000
Value US$489,000
Feng Gigi Qi Officer; CHIEF COMMUNICATIONS OFFICER Officer
Transaction date
Proposed sale
Price
1.80
Quantity 150
Value US$270
Tang Weimin Officer; CHIEF BUSINESS OFFICER Officer
Transaction date
Proposed sale
Price
2.00
Quantity 20,000
Value US$40,000
Zhu Andrew Officer; PRESIDENT AND ACTING CEO Officer
Transaction date
Proposed sale
Price
2.12
Quantity 30,000
Value US$63,600
Li Richard Cheng Officer; CHIEF LEGAL OFFICER Officer
Transaction date
Proposed sale
Price
1.83
Quantity 85,700
Value US$156,831
Feng Gigi Qi Officer; CHIEF COMMUNICATION OFFICER Officer
Transaction date
Proposed sale
Price
1.55
Quantity 20,000
Value US$31,000
Everest Medicines Ltd 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
0.73
Quantity 6,078,555
Value US$4,466,416
Tang Weimin Officer; CHIEF BUSINESS OFFICER Officer
Transaction date
Proposed sale
Price
1.27
Quantity 3,000
Value US$3,810
Hayslip John Officer; CHIEF MEDICAL OFFICER Officer
Transaction date
Proposed sale
Price
2.76
Quantity 29,000
Value US$80,040
Zhu Andrew Officer; PRESIDENT Officer
Transaction date
Proposed sale
Price
2.94
Quantity 97,300
Value US$286,062
Tang Weimin Officer; CHIEF BUSINESS OFFICER Officer
Transaction date
Proposed sale
Price
2.94
Quantity 23,800
Value US$69,972
Li Richard Cheng Officer; CHIEF LEGAL OFFICER Officer
Transaction date
Proposed sale
Price
2.94
Quantity 17,800
Value US$52,332
Yeh Richard Officer; COO interim CFO Officer
Transaction date
Proposed sale
Price
3.08
Quantity 33,000
Value US$101,640
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-07 2026-07-06 S Sale
Xu Cong Claire

SVP, Clinical Development

Officer
14,336 +20.3%
103.47
US$2,387,523 		14,336 +20.3% 103.47 US$2,387,523
2026-06-22 2026-06-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
67,688 -17.3%
433.81
US$2,534,985 		67,688 -17.3% 433.81 US$2,534,985
2026-06-22 2026-06-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
19,334 -27.1%
71.77
US$4,886,838 		19,334 -27.1% 71.77 US$4,886,838
2026-06-02 2026-06-01 S Sale
Xu Cong Claire

SVP, Clinical Development

Officer
3,494 -1.2%
3.94
US$13,766 		3,494 -1.2% 3.94 US$13,766
2026-05-18 2026-05-14 S Sale
Cao Sean Wuxiong

See Remarks

Executive Director
21,399 -37.9%
1.99
US$42,584 		21,399 -37.9% 1.99 US$42,584
2026-05-18 2026-05-14 S Sale
Cao Sean Wuxiong

See Remarks

Executive Director
21,399 -37.9%
1.99
US$42,584 		21,399 -37.9% 1.99 US$42,584
2026-05-14 2026-05-14 PrS Proposed sale
Cao Sean Wuxiong

Officer; CHIEF BUSINESS DEVELOPMENT OFFICER

Officer
9,304
1.99
US$18,534 		9,304 1.99 US$18,534
2026-04-28 2026-04-24 B Purchase
Hagler Mark Arnold

See Remarks

Officer
230,000 +inf%
2.51
US$577,300 		230,000 +inf% 2.51 US$577,300
2026-03-18 2026-03-18 PrS Proposed sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
3,638
2.79
US$10,153 		3,638 2.79 US$10,153
2026-01-02 2026-01-02 PrS Proposed sale
Skelton Joseph W.

Officer; FORMER CFO

Officer
120,000
4.33
US$519,600 		120,000 4.33 US$519,600
2025-12-18 2025-12-18 PrS Proposed sale
Dennis Phillip Andrew

CHIEF MEDICAL OFFICER

Officer
3,431
4.23
US$14,501 		3,431 4.23 US$14,501
2024-07-26 2024-07-26 PrS Proposed sale
KANNAN RAJ

Officer; CEO

Officer
50,000
1.39
US$69,500 		50,000 1.39 US$69,500
2024-07-17 2024-07-17 PrS Proposed sale
KANNAN RAJ

Officer; CEO

Officer
300,000
1.63
US$489,000 		300,000 1.63 US$489,000
2024-03-15 2024-03-15 PrS Proposed sale
Feng Gigi Qi

Officer; CHIEF COMMUNICATIONS OFFICER

Officer
150
1.80
US$270 		150 1.80 US$270
2024-02-08 2024-02-08 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
20,000
2.00
US$40,000 		20,000 2.00 US$40,000
2024-01-05 2024-01-05 PrS Proposed sale
Zhu Andrew

Officer; PRESIDENT AND ACTING CEO

Officer
30,000
2.12
US$63,600 		30,000 2.12 US$63,600
2023-12-29 2023-12-29 PrS Proposed sale
Li Richard Cheng

Officer; CHIEF LEGAL OFFICER

Officer
85,700
1.83
US$156,831 		85,700 1.83 US$156,831
2023-12-26 2023-12-26 PrS Proposed sale
Feng Gigi Qi

Officer; CHIEF COMMUNICATION OFFICER

Officer
20,000
1.55
US$31,000 		20,000 1.55 US$31,000
2023-10-10 2023-10-24 PrS Proposed sale
Everest Medicines Ltd

10% Stockholder

Large shareholder
6,078,555
0.73
US$4,466,416 		6,078,555 0.73 US$4,466,416
2023-09-29 2023-09-29 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
3,000
1.27
US$3,810 		3,000 1.27 US$3,810
2023-07-11 2023-07-11 PrS Proposed sale
Hayslip John

Officer; CHIEF MEDICAL OFFICER

Officer
29,000
2.76
US$80,040 		29,000 2.76 US$80,040
2023-07-05 2023-07-05 PrS Proposed sale
Zhu Andrew

Officer; PRESIDENT

Officer
97,300
2.94
US$286,062 		97,300 2.94 US$286,062
2023-07-05 2023-07-05 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
23,800
2.94
US$69,972 		23,800 2.94 US$69,972
2023-07-05 2023-07-05 PrS Proposed sale
Li Richard Cheng

Officer; CHIEF LEGAL OFFICER

Officer
17,800
2.94
US$52,332 		17,800 2.94 US$52,332
2023-05-01 2023-05-01 PrS Proposed sale
Yeh Richard

Officer; COO interim CFO

Officer
33,000
3.08
US$101,640 		33,000 3.08 US$101,640
Explore more

More insider trading research around NovaBridge Biosciences

More insider trades in KY
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity